

# Quantification of Functional Selectivity at the Human $\alpha_{1A}$ -Adrenoceptor<sup>§</sup>

Bronwyn A. Evans, Natalie Broxton, Jon Merlin, Masaaki Sato,<sup>1</sup> Dana S. Hutchinson, Arthur Christopoulos, and Roger J. Summers

*Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria, Australia*

Received July 8, 2010; accepted October 26, 2010

## ABSTRACT

Although G protein-coupled receptors are often categorized in terms of their primary coupling to a given type of  $G\alpha$  protein subunit, it is now well established that many show promiscuous coupling and activate multiple signaling pathways. Furthermore, some agonists selectively activate signaling pathways by promoting interaction between distinct receptor conformational states and particular  $G\alpha$  subunits or alternative signaling proteins. We have tested the capacity of agonists to stimulate  $Ca^{2+}$  release, cAMP accumulation, and changes in extracellular acidification rate (ECAR) at the human  $\alpha_{1A}$ -adrenoceptor. Signaling bias factors were determined by novel application of an operational model of agonism and compared with the reference endogenous agonist norepinephrine; values significantly different from 1.0 indicated an agonist that promoted receptor conformations distinct from that favored by norepinephrine. Oxymetazoline was a full agonist for ECAR and a

partial agonist for  $Ca^{2+}$  release (bias factor 8.2) but failed to stimulate cAMP production. Phenylephrine showed substantial bias toward ECAR versus  $Ca^{2+}$  release or cAMP accumulation (bias factors 21 and 33, respectively) but did not display bias between  $Ca^{2+}$  and cAMP pathways. Cirazoline and *N*-[5-(4,5-dihydro-1*H*-imidazol-2-yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulfonamide (A61603) displayed bias toward cAMP relative to  $Ca^{2+}$  release (bias factors of 7.4 and 8.6). It is noteworthy that epinephrine, a second endogenous adrenoceptor agonist, did not display bias relative to norepinephrine. Our finding that phenylephrine displayed significant signaling bias, despite being highly similar in structure to epinephrine, indicates that subtle differences in agonist-receptor interaction can affect conformational changes in cytoplasmic domains and thereby modulate the repertoire of effector proteins that are activated.

## Introduction

Although G protein-coupled receptors (GPCRs) are traditionally categorized as  $G_s$ -,  $G_q$ -, or  $G_{i/o}$ -coupled, studies of multiple signaling outputs often indicate that a G protein-coupled receptor has the capacity to interact with more than one G protein subtype as well as alternative signaling or effector proteins such as arrestins. This raises the possibility

that ligands may display functional selectivity, promoting differential coupling of receptors to  $G\alpha$  subunits or G protein-independent pathways (for review, see Galandrin et al., 2007; Kenakin, 2007; Audet and Bouvier 2008; Evans et al., 2010; Kenakin and Miller, 2010). For example, antipsychotic drugs acting at the dopamine  $D_2$  receptor display functional selectivity with respect to  $G_{i/o}$ -mediated decreases in cAMP, compared with receptor recruitment of arrestin-3 (Masri et al., 2008). All clinically effective antipsychotics block arrestin-3 recruitment, despite ranging from partial agonists to inverse agonists when tested for inhibition of cAMP.

In some cases, agonists with only subtle differences in structure still display functional selectivity. Among a series of phenethylamines active at the  $\beta_2$ -AR, cyclopentylbutanephrine,  $\alpha$ -ethylnoradrenaline, and isoetharine are partial agonists for cAMP production relative to isoproterenol but act as full agonists for arrestin-3 recruitment (Drake et al.,

This work was funded by the National Health and Medical Research Council (NHMRC) of Australia [Program Grant 519461]; an NHMRC Senior Research Fellowship (to A.C.); and an NHMRC Career Development Award (to D.S.H.).

<sup>1</sup> Current affiliation: Department of Physiology, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden.

Article, publication date, and citation information can be found at <http://molpharm.aspetjournals.org>.

doi:10.1124/mol.110.067454.

§ The online version of this article (available at <http://molpharm.aspetjournals.org>) contains supplemental material.

**ABBREVIATIONS:** ECAR, extracellular acidification rate; IBMX, 3-isobutyl-1-methylxanthine; AR, adrenoceptor; CHO, Chinese hamster ovary; FBS, fetal bovine serum; HBSS, Hanks' balanced saline solution; A61603, *N*-[5-(4,5-dihydro-1*H*-imidazol-2-yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulfonamide; A23187, calcimycin; U73122, 1-[6-[[17 $\beta$ -methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1*H*-pyrrole-2,5-dione; TM, transmembrane domain.

2008). These three compounds share an ethyl group on the  $\alpha$ C atom, near the  $\text{NH}_3^+$  group that interacts with Asp113 (3.32). There may be a steric effect of the  $\alpha$ -ethyl group that compromises receptor conformational changes linked to G protein activation, without affecting receptor phosphorylation or arrestin binding. In cardiac myocytes, the *S,R*-isomer of fenoterol stimulates substantially higher activation of  $G_{\alpha_{i2}}$  than the *R,R*-isomer, whereas (*R,R*)-fenoterol produces higher activation of  $G_{\alpha_s}$  than (*S,R*)-fenoterol (Woo et al., 2009). This differential  $G_s/G_i$  coupling is apparent in functional assays including myocyte contractility and Erk1/2 phosphorylation, and the authors suggest that agonists selectively able to stimulate  $\beta_2$ -AR  $G_s$  coupling, without stimulating  $\beta_2$ -AR  $G_i$  coupling or  $\beta_1$ -AR activation, may have considerable therapeutic benefit.


In matched cells expressing a given receptor, functional selectivity can be unambiguously demonstrated when two ligands promote a reversal of efficacy or potency between two pathways; that is, drug A has higher efficacy/potency than drug B for pathway 1 but a lower efficacy/potency than drug B for pathway 2 (Kenakin, 2007; Urban et al., 2007; Kenakin and Miller, 2010). However, such observations do not provide capacity for quantification and statistical analysis, and there are reported instances in which drugs do not display reversal of potency or efficacy but clearly promote distinct receptor conformations (for example, Galandrin et al., 2008). The operational model of agonism, originally derived by Black and Leff (1983), can provide a means of quantifying signaling bias by comparing  $\tau/K_A$  ratios among agonists (Figueroa et al., 2009; Gregory et al., 2010; Kenakin and Miller, 2010; Koole et al., 2010). In this model, the parameter  $\tau$  encompasses receptor density and the efficacy of the agonist, and  $K_A$  is the equilibrium dissociation constant of the agonist-receptor complex. The composite parameter,  $\tau/K_A$ , is thus a convenient "transduction ratio" (Kenakin and Miller, 2010) that can

account for functional selectivity in the activity of drugs with high affinity/low efficacy or low affinity/high efficacy.

In the current study, we have used this approach to calculate bias factors for agonists acting at the human  $\alpha_{1A}$ -adrenoceptor (AR). The three  $\alpha_1$ -ARs preferentially stimulate coupling to  $G_q$ , activating phospholipase C, increasing intracellular levels of inositol (1,4,5)-triphosphate and intracellular  $\text{Ca}^{2+}$ , and releasing diacylglycerol that in turn activates protein kinase C isoforms. Studies in tissues that endogenously express  $\alpha_1$ -ARs, or in recombinant cells expressing each of the  $\alpha_1$ -AR subtypes, have also demonstrated activation of phospholipase  $A_2$ , phospholipase D, adenylate cyclase, and mitogen-activated protein kinases (Perez et al., 1993; Graham et al., 1996; Zhong and Minneman, 1999; Piascik and Perez, 2001). We have examined the ability of  $\alpha_{1A}$ -ARs stably expressed in CHO-K1 cells to stimulate  $\text{Ca}^{2+}$  release, cAMP accumulation, and changes in extracellular acidification rate (ECAR) upon agonist exposure. We compared the endogenous agonist norepinephrine, another two phenethylamines (methoxamine and phenylephrine), and three imidazolines, cirazoline, oxymetazoline, and A61603 (Fig. 1). All six agonists stimulated release of intracellular  $\text{Ca}^{2+}$  and ECAR measured in a cytosensor microphysiometer. Oxymetazoline was a partial agonist for  $\text{Ca}^{2+}$  release and a full agonist in the cytosensor yet failed to stimulate cAMP production even at high concentrations. By calculating bias factors for the agonists relative to norepinephrine, we have found several clear and quantitative indications of functional selectivity. In contrast to this group of compounds, the two endogenous agonists norepinephrine and epinephrine showed no bias relative to each other.

## Materials and Methods

**Materials.** Sources of drugs were as follows: [ $^{125}\text{I}$ ]HEAT (2-[ $\beta$ -(4-hydroxy-3-[ $^{125}\text{I}$ ]iodophenyl) ethylamino-methyl]tetralone) (Pro-



**Fig. 1.** Chemical structures of  $\alpha_{1A}$ -AR agonists used in the study. A, phenethylamines. B, imidazolines.

Search, Melbourne, Australia); [<sup>3</sup>H]prazosin (PerkinElmer Life and Analytical Sciences, Waltham, MA); (-)-norepinephrine bitartrate, phenylephrine, and phentolamine HCl (Sigma, St. Louis, MO); methoxamine, oxymetazoline, cirazoline, and *N*-[5-(4,5-dihydro-1*H*-imidazol-2-yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulfonamide (A61603; Tocris Bioscience, Ellisville, MO); Dulbecco's modified Eagle's medium/Ham's F12 50:50 mix, fetal bovine serum, glutamine, penicillin/streptomycin (ThermoTrace Pty., Ltd., Noble Park, VIC, Australia); Platinum Pfx DNA polymerase, Lipofectamine, phenol red-free OptiMEM, and Fluoro-4 (Invitrogen, Carlsbad, CA); and G418 and IBMX (Sigma). Cytosensor consumables were from Selby Biolab (Clayton Nth, VIC, Australia), except for Costar transwell cups (Corning Life Sciences, Lowell, MA).

**Cloning of the Human  $\alpha_{1A}$ -AR.** Plasmid containing the human  $\alpha_{1A-4}$ -AR cDNA was a gift from Dr. Thomas Chang (Roche Bioscience, Palo Alto, CA). The coding region of this receptor was subcloned into the multiple cloning site of pcDNA3.1. The  $\alpha_{1A-4}$ -AR cDNA was converted to the  $\alpha_{1A-1}$ -AR as follows. A silent mutation was introduced into the  $\alpha_{1A-4}$ -AR construct using the QuikChange mutagenesis kit (Stratagene, La Jolla, CA) to generate a BsrGI restriction site (TGT ACC→TGT ACA) corresponding to Cys<sup>419</sup> Thr<sup>420</sup>, immediately upstream of the point at which the four  $\alpha_{1A}$ -AR splice variants differ (Chang et al., 1998). The 3' end of the  $\alpha_{1A-1}$ -AR coding region was generated by polymerase chain reaction on human genomic DNA, using Platinum Pfx high-fidelity DNA polymerase. The forward primer incorporated the BsrGI site (underlined; 5' AATCCTCCTG-TACAACAGCCCCGGGTGAG 3') and the reverse primer included the  $\alpha_{1A-1}$ -AR termination codon and a downstream XbaI site (underlined; 5' CCTCTGCATCTAGACTGTCCTAGACTTCCTC 3'). The  $\alpha_{1A-1}$ -AR polymerase chain reaction fragment was digested with BsrGI and XbaI, then ligated into pcDNA3.1- $\alpha_{1A-4}$ -AR plasmid from which the corresponding cassette had been removed. The complete  $\alpha_{1A-1}$ -AR insert and junctions with pcDNA3.1 were checked by DNA sequencing on both strands (Micromon; Monash University, Parkville, VIC, Australia).

**Cell Culture and Production of Clones Stably Expressing  $\alpha_{1A}$ -ARs.** Chinese hamster ovary (CHO-K1) cells were grown in a 50:50 Dulbecco's modified Eagle's medium/Ham's F12 medium supplemented with 10% (v/v) fetal bovine serum (FBS), glutamine (2 mM), penicillin (100 units/ml), and streptomycin (100  $\mu$ g/ml) at 37°C with 5% CO<sub>2</sub>. Transfections were performed using Lipofectamine, and the transfected cells were selected in media containing 800  $\mu$ g/ml G418 and maintained in media containing 400  $\mu$ g/ml G418. Clonal cell lines were isolated by screening G418-resistant colonies and preliminary screening of clones was made using a single point [<sup>3</sup>H]prazosin (2000 pM) whole-cell binding assay. Suitable clones were amplified and receptor levels determined in saturation binding assays using <sup>125</sup>I-HEAT.

**Radioligand Binding Studies.** Cells were harvested as described previously by Hutchinson et al., (2002). In brief, cells from a 75-cm<sup>2</sup> flask were washed twice with HEPES-buffered saline and scraped from flasks with lysis buffer (25 mM Tris, pH 7.5 at room temperature, 1 mM EDTA, 200  $\mu$ g/ml bacitracin, 10  $\mu$ g/ml leupeptin, 2.5  $\mu$ g/ml pepstatin A, and 2.5  $\mu$ g/ml aprotinin). Cells were homogenized with a Dounce homogenizer and centrifuged at low speed (1000g, 10 min) to remove cell debris. Supernatants were pooled and centrifuged (39,000g, 15 min, 4°C). The pellet was homogenized in binding buffer (50 mM Tris, pH 7.4, 5 mM MgCl<sub>2</sub>, 1 mM EDTA, 200  $\mu$ g/ml bacitracin, 10  $\mu$ g/ml leupeptin, 2.5  $\mu$ g/ml pepstatin A, and 2.5  $\mu$ g/ml aprotinin) and frozen at -70°C until required. Membranes (10–20  $\mu$ g of protein) were incubated with <sup>125</sup>I-HEAT (20–1200 pM) in a total volume of 100  $\mu$ l for 90 min at room temperature (21°C). Phentolamine (100  $\mu$ M) was used to define nonspecific binding. Competition binding experiments were conducted using a range of concentrations of unlabeled ligand and <sup>125</sup>I-HEAT (500 pM), also at room temperature for 90 min (Sharpe et al., 2003). Reactions were terminated by rapid filtration through GF/C filters presoaked for 30 min in 0.5% polyethylenimine using a Packard Filtermate cell har-

vester. Filters were washed three times with wash buffer (50 mM Tris, pH 7.4, 4°C), dried, and 25  $\mu$ l of Microscint O (PerkinElmer Life and Analytical Sciences) added and radioactivity counted on a Packard TopCount. Protein concentrations were quantitated using the Lowry et al. (1951) assay. All experiments were performed in duplicate using five different membrane preparations.

**Measurement of Intracellular Free Ca<sup>2+</sup> Concentration.** CHO-K1 cells expressing the  $\alpha_{1A}$ -AR were seeded at  $5 \times 10^4$  cells per well in 96-well plates overnight. On the day of the experiment, the media were removed and cells were washed three times in a modified Hanks' balanced saline solution (HBSS; 150 mM NaCl, 2.6 mM KCl, 1.18 mM MgCl<sub>2</sub>·2H<sub>2</sub>O, 10 mM D-glucose, 10 mM HEPES, 2.2 mM CaCl<sub>2</sub>·2H<sub>2</sub>O, and 2 mM probenecid, pH 7.4) containing 0.5% (w/v) bovine serum albumin. In light-diminished conditions, cells were treated with fluoro-4 [0.1% (v/v) in modified HBSS, 1 h, 37°C]. Excess fluoro-4 not taken up by the cells was removed by washing twice in modified HBSS and then incubated for a further 30 min before the assay plate was transferred to a FlexStation (Molecular Devices, Sunnyvale, CA). Real-time fluorescence measurements were recorded every 1.7 s over 200 s, with drug additions occurring after 17 s, at an excitation wavelength of 485 nm and reading emission wavelength of 520 nm. All experiments were performed in duplicate. Agonist responses represent the difference between basal fluorescence and peak [Ca<sup>2+</sup>]<sub>i</sub> measurements expressed as a percentage of the response to calcimycin (A23187) (1  $\mu$ M) in each experiment.

**cAMP Accumulation Studies.** Cells were seeded into 96-well plates at  $10^4$  cells/well in media with 0.5% (v/v) FBS the night before the experiment. On the day of the experiment, the media were replaced with stimulation buffer (1 mg/ml BSA, 0.5 mM IBMX, and 5 mM HEPES, pH 7.4, in Hanks' balanced salt solution, 50  $\mu$ l/well). Cells were exposed to agonists (diluted to 2 $\times$  final concentration in stimulation buffer, 50  $\mu$ l/well) for 30 min at 37°C, then reactions were terminated by addition of 100  $\mu$ l of lysis buffer [1 mg/ml BSA, 0.3% (v/v) Tween 20, 5 mM HEPES, and 1 mM IBMX, pH 7.4]. cAMP was assayed using  $\alpha$ Screen in an EnVision plate reader (PerkinElmer Life and Analytical Sciences, VIC, Australia). Responses to forskolin (10<sup>-4</sup> M) were determined in parallel with agonist-stimulated cAMP accumulation for each batch of cells, and results are expressed as a percentage of the response to forskolin. All experiments were performed in duplicate, and *n* is the number of independent experiments.

**Cytosensor Microphysiometer Studies.** The cytosensor microphysiometer (Molecular Devices) is a light-addressable silicon sensor-based device that measures increases in the metabolic activity of isolated cells as increases in ECAR (McConnell et al., 1992). Cells were seeded into 12-mm Costar transwell cups (3- $\mu$ m pore size; Corning Life Sciences) at  $5 \times 10^5$  cells per cup in media with 0.5% FBS and allowed to grow overnight. The next day, the assembled cups were placed in the sensor chambers in the cytosensor and perfused with modified RPMI 1640 medium (Molecular Devices) at 100  $\mu$ l/min at 37°C. After initial set-up, cells were superfused with media for 2 h to stabilize baseline extracellular acidification rates, and then cumulative concentration-response curves were constructed for each agonist. Each concentration was perfused for 14 min, consisting of seven 2-min pump cycles during which the flow was stopped for the last 40 s and the acidification rate measured for 30 s. The maximum reading from the seven-cycle recording corresponding to each drug concentration was expressed as a percentage of the basal acidification rate measured over a period of 10 min before the addition of agonist. All drugs were diluted in medium and concentration-response experiments were performed in the presence of (-) propranolol (10<sup>-6</sup> M) to block any contributions from endogenous  $\beta_2$ -AR. Results were expressed as percentage of basal ECAR, and *n* values represent cells grown in different flasks before plating into the transwell cups.

**Data Analysis.** All values are expressed as mean  $\pm$  S.E.M. of *n*. Data were analyzed using nonlinear curve fitting (Prism ver. 5.02; GraphPad Software, San Diego, CA) to obtain pEC<sub>50</sub> values for the



cytosensor microphysiometer, cAMP accumulation, and  $[Ca^{2+}]_i$  assays, or  $pK_i$ ,  $pK_D$ , and  $B_{max}$  values from radioligand binding assays. To quantify signaling bias, agonist concentration response curves were analyzed by nonlinear regression using an operational model of agonism (Black and Leff, 1983; Gregory et al., 2010) in a method similar to that described by Figueroa et al. (2009), to define  $\tau/K_A$  ratios for each agonist, for each pathway:

$$Y = \text{Basal} + \frac{(E_m - \text{Basal}) \times \text{TR}^n \times [A]^n}{[A]^n \times \text{TR}^n + \left(1 + \frac{[A]}{K_A}\right)^n} \quad (1)$$

where  $E_m$  is the maximal possible response of the system (not the agonist), Basal is the basal level of response in the absence of agonist,  $K_A$  denotes the functional equilibrium dissociation constant of the agonist for the ground (G protein-uncoupled) state of the receptor,  $n$  is the slope of the transducer function that links occupancy to response, and TR (transduction ratio) is the ratio of  $\tau/K_A$ , where  $\tau$  is an index of the coupling efficiency (or efficacy) of the agonist—this parameter incorporates the affinity of the agonist for the active state of the receptor that triggers signaling, as well as the efficiency of coupling of the receptor to its cognate G protein(s) and subsequent cellular stimulus-response transduction mechanisms (Leff and Harper, 1989). Note that  $K_A$  values are derived directly from the nonlinear regression analysis of agonist concentration-response curves. The estimated TR values were used in the comparison of functional selectivity mediated by each agonist across the various pathways, as described under *Results*. A detailed exploration of this method for determining agonist signaling bias will be presented separately (T. Kenakin, R. Novick, C. Watson, V. Muniz-Medina, and A. Christopoulos, manuscript in preparation).

## Results


**Expression of the  $\alpha_{1A}$ -AR in CHO-K1 Cells.** Based on saturation binding with  $^{125}I$ -HEAT, the  $\alpha_{1A}$ -AR clone chosen for these studies displayed a  $B_{max}$  value of  $531 \pm 94$  fmol/mg protein and a  $pK_D$  of  $9.2 \pm 0.09$ . Further characterization of the  $\alpha_{1A}$ -AR was carried out with competition binding experiments using the agonists norepinephrine, methoxamine, phenylephrine, oxymetazoline, cirazoline, and A61603. All of the agonists competed for [ $^{125}I$ ]HEAT binding, with binding curves fitting a single site isotherm. The rank order of binding affinities for the  $\alpha_{1A}$ -AR agonists was oxymetazoline ( $pK_i$   $7.5 \pm 0.2$ ) = A61603 ( $7.3 \pm 0.1$ ) > cirazoline ( $6.7 \pm 0.2$ )  $\gg$  norepinephrine ( $5.3 \pm 0.1$ ) > phenylephrine ( $4.9 \pm 0.1$ ) = methoxamine ( $4.8 \pm 0.1$ ) ( $n = 3-7$ ). Note that imidazoline agonists have substantially higher affinity for the  $\alpha_{1A}$ -AR than the phenethylamines.

**Effects of  $\alpha_{1A}$ -AR Agonists on Intracellular  $Ca^{2+}$  Release.** In CHO-K1 cells expressing the  $\alpha_{1A}$ -AR, all the agonists stimulated  $Ca^{2+}$  release (Fig. 2, Table 1).  $E_{max}$  values

ranged from 97.4% for A61603 (relative to  $1 \mu\text{M}$  A23187) down to 78.4% for oxymetazoline. It is noteworthy that norepinephrine and phenylephrine behaved as high-efficacy, low-affinity agonists, because the ratio of the apparent binding affinity ( $K_i$ ) to  $EC_{50}$  is approximately 1700. Such a high “amplification” ratio (Strange, 2008) reflects substantially higher agonist affinity for the active state(s) than for the inactive state of the receptor and/or high efficiency of signal transduction for the measured pathway, in this case  $Ca^{2+}$  release. In contrast to norepinephrine and phenylephrine, oxymetazoline and cirazoline display only 36- and 47-fold amplification factors. A61603 and methoxamine differ in  $pK_i$  for the  $\alpha_{1A}$ -AR by more than 2 log units but display similar amplification of the response relative to their binding affinities (250- and 320-fold, respectively).

### Effects of $\alpha_{1A}$ -AR Agonists on cAMP Accumulation.

All three  $\alpha_1$ -AR subtypes promote agonist-stimulated  $G_q$  activation and  $Ca^{2+}$  release, but only the  $\alpha_{1A}$ - and  $\alpha_{1B}$ -AR stimulate adenylate cyclase and cAMP production (Shibata et al., 2003). This suggests that the receptor coupling determinants for the  $Ca^{2+}$  and cAMP pathways differ, and thus that the immediate postreceptor step for each of these pathways is distinct. We found that incubation of CHO- $\alpha_{1A}$ -AR cells with norepinephrine, phenylephrine, methoxamine, cirazoline, or A61603 stimulated concentration-dependent increases in cAMP accumulation as shown in Fig. 3. Concentration-response curves were also performed in the presence of inhibiting concentrations of propranolol ( $10^{-6}$  M) to block any endogenous  $\beta$ -ARs. This did not affect cAMP responses, demonstrating that endogenous  $\beta$ -ARs were not responsible for the  $\alpha_{1A}$ -AR agonist-stimulated cAMP accumulation (data not shown). In addition, no response was seen in nontransfected CHO-K1 cells stimulated with norepinephrine (data not shown). In contrast to the other agonists, oxymetazoline failed to increase cAMP production above basal levels at concentrations up to  $10^{-4}$  M. To test for possible physiological antagonism of responses to oxymetazoline mediated by endogenous  $\alpha_2$ -AR in CHO-K1 cells, experiments were performed in the presence of the  $\alpha_2$ -AR antagonist rauwolscine ( $10^{-7}$  M). These experiments failed to reveal cAMP accumulation in response to oxymetazoline. To test whether oxymetazoline was directing strong coupling of the  $\alpha_{1A}$ -AR to  $G_i$ , thereby cancelling out any stimulatory effect on cAMP accumulation, cells were pretreated with pertussis toxin 16 h before agonist stimulation. This likewise failed to reveal any cAMP accumulation in response to oxymetazoline (data not shown). cAMP responses are expressed as a percentage of the control forskolin ( $10^{-4}$  M) response, and  $E_{max}$  and potency



**Fig. 2.** Concentration-response curves for stimulation of  $Ca^{2+}$  release by the  $\alpha_{1A}$ -AR. CHO-K1 cells stably expressing the human  $\alpha_{1A}$ -AR were treated with 0.1% fluoro-4 at  $37^\circ\text{C}$  for 1 h then washed and incubated for a further 30 min. Real-time fluorescence measurements were recorded every 1.7 s, with drug additions occurring after 17 s. Agonist responses represent the difference between basal fluorescence and the peak  $[Ca^{2+}]_i$  (reached within 20 s of agonist addition), expressed as a percentage of the response to the  $Ca^{2+}$  ionophore A23187 ( $1 \mu\text{M}$ ). Dose-dependent  $Ca^{2+}$  release was stimulated by phenethylamine (A) and imidazoline (B) agonists. Values are means  $\pm$  S.E.M. of six independent experiments. In B, the norepinephrine curve is shown as a dashed line for comparison.


values for each agonist are summarized in Table 1.  $E_{\max}$  values were similar for the three phenethylamines and A61603, whereas cirazoline was a partial agonist. It is striking that all of the drugs able to activate cAMP accumulation do so with  $pEC_{50}$  values very close to their affinity values.

TABLE 1

Potency ( $pEC_{50}$ ), maximum response ( $E_{\max}$ ), and  $\alpha$  value ( $E_{\max}$  relative to norepinephrine) of agonists at the human  $\alpha_{1A}$ -AR

	Ca <sup>2+</sup> Release	cAMP	ECAR
Norepinephrine			
$pEC_{50}$	8.58 ± 0.07	5.55 ± 0.05	7.36 ± 0.04
$E_{\max}$	92.8 ± 1.7	27.3 ± 0.5	152.2 ± 1.1
$\alpha$	1.00 (6)	1.00 (5)	1.00 (4)
Methoxamine			
$pEC_{50}$	7.44 ± 0.05	4.39 ± 0.06	6.95 ± 0.04
$E_{\max}$	87.7 ± 1.6	25.7 ± 0.8	146.5 ± 0.9
$\alpha$	0.95 (6)	0.94 (5)	0.96 (4)
Phenylephrine			
$pEC_{50}$	8.10 ± 0.06	4.93 ± 0.06	8.29 ± 0.07
$E_{\max}$	91.7 ± 1.6	23.4 ± 0.6	148.3 ± 1.6
$\alpha$	0.99 (6)	0.86 (5)	0.97 (4)
Oxymetazoline			
$pEC_{50}$	8.86 ± 0.10	N.D.	8.55 ± 0.05
$E_{\max}$	78.4 ± 2.4	N.D.	146.6 ± 1.0
$\alpha$	0.84 (6)	N.D.	0.96 (4)
Cirazoline			
$pEC_{50}$	8.54 ± 0.12	6.89 ± 0.08	8.13 ± 0.03
$E_{\max}$	97.0 ± 3.5	14.8 ± 0.5	148.5 ± 0.6
$\alpha$	1.05 (6)	0.54 (5)	0.98 (4)
A61603			
$pEC_{50}$	9.63 ± 0.06	7.59 ± 0.05	9.09 ± 0.05
$E_{\max}$	97.4 ± 2.0	28.6 ± 0.5	147.6 ± 1.1
$\alpha$	1.05 (6)	1.05 (5)	0.97 (4)

N.D., not determined.



**Fig. 4.** Concentration-response curves for changes in extracellular acidification rate measured in the cytosensor microphysiometer. Cells stably expressing the  $\alpha_{1A}$ -AR were grown overnight in transwell cups then placed in cytosensor chambers and perfused with modified low-buffered RPMI 1640 medium. After 2 h pre-equilibration, the basal acidification rate was measured over a period of 10 min, and then successive agonist concentrations were added at 14-min intervals. The maximum reading from the seven-cycle recording corresponding to each drug concentration was expressed as a percentage of the basal acidification rate. Changes in ECAR were stimulated by phenethylamine (A) and imidazoline (B) agonists in a dose-dependent manner. Values are means ± S.E.M. of four independent experiments. In B, the norepinephrine curve is shown as a dashed line for comparison.

**Effects of  $\alpha_{1A}$ -AR Agonists on ECAR.** To examine additional pathways that may be activated by the  $\alpha_{1A}$ -AR, the cytosensor microphysiometer was used as a measure of total cellular activity stimulated by agonists. Incubation of cells stably expressing the  $\alpha_{1A}$ -AR with agonists stimulated concentration-dependent increases in extracellular acidification rate (ECAR; Fig. 4).  $E_{\max}$  values ranged from increases of 146.5 to 152.2% basal (Table 1). In essence, all of the compounds tested were full agonists relative to norepinephrine, representing a substantial change in the behavior of oxymetazoline and cirazoline compared with Ca<sup>2+</sup> release or cAMP responses. As seen in the Ca<sup>2+</sup> release assay, there were substantial differences in the degree of amplification displayed by each agonist, varying from 2350-fold for phenylephrine down to 9-fold for oxymetazoline. Unlike Ca<sup>2+</sup> release, however, norepinephrine promoted only 105-fold amplification, approximately 20-fold lower than that seen with phenylephrine.

**Analysis of Functional Selectivity at the  $\alpha_{1A}$ -AR.** Our data indicated that there are interesting differences in agonist activity between the three measured signaling outputs. We thus carried out a further analysis of this data to test the hypothesis that at least some agonists display functional selectivity; that is, they preferentially induce or stabilize different receptor conformations that in turn couple to two or more signaling pathways (Kenakin, 2007; Urban et al., 2007; Evans et al., 2010; Kenakin and Miller, 2010). One hallmark of functional selectivity is that two agonists show a reversal in efficacy between two signaling assays, although a reversal

**Fig. 3.** Concentration-response curves for stimulation of cAMP accumulation by the  $\alpha_{1A}$ -AR. CHO-K1 cells stably expressing the  $\alpha_{1A}$ -AR were exposed to agonists for 30 min in stimulation buffer containing 0.5 mM IBMX to inhibit phosphodiesterases. Responses to forskolin ( $10^{-4}$  M) were determined in parallel with agonist-stimulated cAMP accumulation for each batch of cells, and results are expressed as a percentage of the response to forskolin. A dose-dependent cAMP response was stimulated by norepinephrine, phenylephrine, and methoxamine (A), cirazoline and A61603 (B), but not oxymetazoline. Values are means ± S.E.M. of four to five independent experiments. In B, the norepinephrine curve is shown as a dashed line for comparison.

in potency between two agonists can also be accommodated only by the involvement of distinct receptor conformations (Kenakin, 2007). Among the data presented in Table 1, there were no reversals in  $E_{max}$  between agonists; however, there were several instances of a reversal of potency. As shown in Fig. 2, oxymetazoline stimulated a small cAMP response at 1 mM and thus exhibited very low potency even though no  $pEC_{50}$  value could be derived. Oxymetazoline had higher potency for  $Ca^{2+}$  release than phenylephrine but clearly lower potency for cAMP. Likewise, oxymetazoline had higher potency for both  $Ca^{2+}$  release and ECAR than methoxamine but lower potency for cAMP accumulation. It is noteworthy that phenylephrine had higher potency for ECAR than norepinephrine but lower potency for  $Ca^{2+}$  release.

Although these reversals in potency indicate functional selectivity, there are two major limitations. First, a subjective analysis of the data does not allow us to ascribe statistical significance to bias in drug activity across the three signaling endpoints. Second, although a reversal in efficacy or potency between drugs may be a sufficient condition for demonstrating functional selectivity, there is evidence that such reversals are not a necessary condition (Evans et al., 2010). Thus, we applied an operational model of agonism (eq. 1) to derive quantitative measures of functional selectivity between agonists for the different signaling assays. To exclude possible bias introduced by the cellular host system (as evidenced by the substantial differences in response amplification displayed by norepinephrine across the three assays), the transduction ratios derived from application of the operational model of agonism were normalized to those of a reference agonist, in this case the endogenous agonist, norepinephrine. Under these conditions, if the test agonist and the reference agonist activate the two pathways via a common receptor conformation, the bias factor should be 1.0, irrespective of differences in response amplification between pathways. In contrast, significant deviation of bias factors from 1.0 indicates the involvement of distinct conformations for the different agonists. Table 2 shows the logarithms of the operational model  $\tau/K_A$  ratios for each pathway ( $\log TR$ ), the  $\log TR$  values normalized to that of norepinephrine ( $\log TR_n$ ), and the final bias factor calculations for signaling by the  $\alpha_{1A}$ -AR (difference between  $\log TR_n$  values for a given agonist across different pathways; see Supplemental Table 1 for statistical analysis of data).

Phenylephrine and oxymetazoline showed significant bias toward ECAR compared with  $Ca^{2+}$  release. In the case of phenylephrine, the bias factor of 21 reflects a high  $\tau/K_A$  ratio for ECAR relative to norepinephrine, despite the lower  $\tau/K_A$  ratio for  $Ca^{2+}$  release. A high bias factor of 8.2 was observed for oxymetazoline because, unlike norepinephrine, this drug displayed the same  $\tau/K_A$  ratio for ECAR and  $Ca^{2+}$  release ( $\log \tau/K_A$  values of 8.46 and 8.52, respectively). Phenylephrine also displayed a high bias factor of 33 between ECAR and cAMP accumulation. Again, this reflects the fact that the cAMP  $\tau/K_A$  ratio was substantially lower for phenylephrine than for norepinephrine, whereas the ECAR ratio was higher. The same is true to a lesser extent for methoxamine (bias factor 4.0) but was not seen in the case of the two imidazolines. A different pattern emerged between  $Ca^{2+}$  release and cAMP accumulation. Here, the two phenethylamines (methoxamine and phenylephrine) showed no significant bias relative to norepinephrine, whereas the two

**TABLE 2**
**Calculation of bias factors for phenethylamine and imidazoline agonists at the  $\alpha_{1A}$ -AR**

 LogTR is the log of the transduction ratio ( $\tau/K_A$ ), and  $\log TR_n$  values are normalized to the logTR for norepinephrine. Bias factors in bold are significantly different from 1.0. To avoid propagation of error as a result of multiple data manipulation steps, Student's *t* tests were carried out on the raw logTR data rather than data normalized to norepinephrine (see Supplemental Table 1).

Agonist	$Ca^{2+}$ Release ( <i>n</i> = 6)		cAMP ( <i>n</i> = 5)		ECAR ( <i>n</i> = 4)		$\log TR_n$ [pathway 1-pathway 2]		
	logTR	$\log TR_n$	logTR	$\log TR_n$	logTR	$\log TR_n$	[cAMP- $Ca^{2+}$ ] (Bias Factor)	[ECAR-cAMP] (Bias Factor)	[ECAR- $Ca^{2+}$ ] (Bias Factor)
Norepinephrine	8.46 ± 0.14	0.00 ± 0.19	5.48 ± 0.11	0.00 ± 0.16	7.48 ± 0.11	0.00 ± 0.18	0.00 ± 0.25 (1.0)	0.00 ± 0.24 (1.0)	0.00 ± 0.26 (1.0)
Methoxamine	7.24 ± 0.14	-1.22 ± 0.20	4.27 ± 0.13	-1.21 ± 0.18	6.87 ± 0.11	-0.61 ± 0.18	0.01 ± 0.26 (1.0)	0.60 ± 0.25* (4.0)	0.61 ± 0.26 (4.0)
Phenylephrine	7.94 ± 0.14	-0.52 ± 0.20	4.76 ± 0.14	-0.72 ± 0.18	8.27 ± 0.12	0.79 ± 0.18	-0.20 ± 0.27 (0.63)	1.52 ± 0.26*** (33)	1.31 ± 0.27** (21)
Oxymetazoline	8.52 ± 0.15	0.06 ± 0.21	N.A.	N.A.	8.46 ± 0.12	0.98 ± 0.19	N.A.	N.A.	0.91 ± 0.28* (8.2)
Cirazoline	8.57 ± 0.14	0.11 ± 0.20	6.46 ± 0.22	0.98 ± 0.25	8.10 ± 0.11	0.62 ± 0.18	0.87 ± 0.32* (7.4)	-0.36 ± 0.31 (0.44)	0.51 ± 0.27 (3.2)
A61603	9.58 ± 0.15	1.12 ± 0.20	7.54 ± 0.12	2.06 ± 0.16	9.03 ± 0.11	1.55 ± 0.19	0.94 ± 0.26*** (8.6)	-0.51 ± 0.25 (0.31)	0.43 ± 0.28 (2.7)

 \*  $P < 0.05$ .

 \*\*  $P < 0.01$ .

 \*\*\*  $P < 0.001$ .

N.A., not applicable.

imidazolines (cirazoline and A61603) showed clear 7.4- and 8.6-fold bias, respectively, toward cAMP signaling. Given that there was no reversal of potency between norepinephrine and cirazoline or A61603 for cAMP accumulation versus  $\text{Ca}^{2+}$  release, this result illustrates the power of being able to quantify functional selectivity using the operational model.

To check that these findings of signaling bias were not artifacts of the particular clonal cell line used or receptor abundance, we repeated the analysis using CHO-K1 cells expressing the  $\alpha_{1A}$ -AR with a  $B_{\text{max}}$  of 204 fmol/mg protein. The key finding was still evident in these cells: the bias factors for phenylephrine relative to norepinephrine were 37 for ECAR compared with  $\text{Ca}^{2+}$  release and 34 for ECAR versus cAMP, whereas there was no bias between the  $\text{Ca}^{2+}$  and cAMP pathways (bias factor 0.9).


**Endogenous Agonists for the  $\alpha_{1A}$ -AR Do Not Display Functional Selectivity.** Phenylephrine displayed a substantially higher capacity than norepinephrine to activate signaling pathways leading to changes in ECAR, suggesting that it preferentially induces or stabilizes an  $\alpha_{1A}$ -AR conformation that couples strongly to one or more of these pathways. In contrast, the lack of bias between cAMP and  $\text{Ca}^{2+}$  indicates that the conformation associated with each of phenylephrine and norepinephrine is coupled equally well to pathways mediating  $\text{Ca}^{2+}$  release and cAMP accumulation. As shown in Fig. 1, norepinephrine and phenylephrine share the *meta*-hydroxyl group on the ring structure, and the chiral  $\beta$ -hydroxyl, but there are two key differences in their chemical structure. Norepinephrine has a catechol ring with both the *meta*- and a *para*-hydroxyl group, whereas phenylephrine lacks the *para*-hydroxyl. On the other hand, phenylephrine has a methyl substituent on the active amine group that is not present in norepinephrine. We analyzed signaling bias between norepinephrine and epinephrine because the latter

has both the catechol ring and the *N*-methyl group (Fig. 5A). As shown in Fig. 5, B–D, norepinephrine and epinephrine are full agonists for each of the signaling pathways. Epinephrine always has somewhat higher potency than norepinephrine (Table 3), but there is no signaling bias between these compounds based on  $\pi/K_A$  ratio calculations (Tables 4 and 5).

## Discussion

We show in this study that phenethylamine and imidazole agonists display functional selectivity at the human  $\alpha_{1A}$ -AR. In particular, phenylephrine shows substantial bias toward ECAR versus  $\text{Ca}^{2+}$  release or cAMP accumulation compared with norepinephrine but does not display any bias between the  $\text{Ca}^{2+}$  and cAMP pathways. The additional endogenous agonist, epinephrine, does not show bias relative to norepinephrine in any of the signaling outputs measured. Our findings indicate no overall class effect between the phenethylamines and imidazolines, because oxymetazoline is unable to stimulate cAMP accumulation, whereas it shows significant bias toward ECAR relative to  $\text{Ca}^{2+}$  release. The other two imidazolines, however, both display bias toward cAMP relative to  $\text{Ca}^{2+}$  release but no bias toward ECAR. It is noteworthy that we can now draw conclusions about the functional selectivity of  $\alpha_{1A}$ -AR agonists because we have an analytical method that provides a numerical measure of bias.

Although many  $\alpha_{1A}$ -AR responses, including intracellular  $\text{Ca}^{2+}$  release, are produced via the classic  $G_q$  pathway, coupling of  $\alpha_1$ -ARs to additional signaling pathways has been observed in recombinant systems and tissues expressing endogenous receptors (Morgan et al., 1983; Johnson and Minneman, 1986). Although early studies suggested that  $\alpha_1$ -AR mediated cAMP accumulation was secondary to  $G_q$  coupling (Perez et al., 1993), other studies favor  $\alpha_1$ -AR- $G_s$  coupling.



**Fig. 5.** Comparison of the activity of the endogenous agonists norepinephrine and epinephrine at the human  $\alpha_{1A}$ -AR. A, structure of epinephrine. B–D, concentration-response curves for  $\text{Ca}^{2+}$  release, cAMP, and changes in ECAR were determined as described in the legends to Figs. 2 to 4. Values are means  $\pm$  S.E.M. of seven to nine independent experiments.



Horie et al. (1995) showed that in CHO- $\alpha_{1B}$ -AR cells, norepinephrine-stimulated cAMP accumulation was inhibited by an antibody against the  $G_{\alpha_s}$  C terminus. The phospholipase C inhibitor 1-[6-[[17 $\beta$ -methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1*H*-pyrrole-2,5-dione (U73122) abolished increases in intracellular  $Ca^{2+}$  but had no effect on cAMP accumulation. In CHO-K1 cells expressing each of the  $\alpha_1$ -ARs, phenylephrine stimulation of the  $\alpha_{1A}$ - and  $\alpha_{1B}$ -AR increased inositol phosphate and cAMP accumulation, whereas the  $\alpha_{1D}$ -AR activated only inositol phosphate production (Shibata et al., 2003). Thus in CHO- $\alpha_{1D}$ -AR cells, activation of the  $G_q$  pathway was not sufficient for stimulation of cAMP. Our data on the  $\alpha_{1A}$ -AR also support a dissociation between the  $G_q$  and cAMP pathways, in that cirazoline and A61603 promoted significant bias relative to norepinephrine between  $Ca^{2+}$  release and cAMP accumulation. In addition, oxymetazoline was able to stimulate  $Ca^{2+}$  release but failed to increase cAMP accumulation. It is noteworthy that although oxymetazoline, cirazoline, and A61603 share some common structural elements (Fig. 1), they clearly produce distinct  $\alpha_{1A}$ -AR conformations that display varying efficiency for cAMP accumulation.

There is increasing understanding of the way in which drugs activate GPCRs derived from recent crystal structures of the  $\beta_1$ -AR,  $\beta_2$ -AR, and adenosine  $A_{2A}$  receptors (Rosenbaum et al., 2007; Jaakola et al., 2008; Warne et al., 2008), biophysical and structure-function studies (Swaminath et al., 2004; Yao et al., 2006; Yao et al., 2009), computer modeling and virtual ligand screening (Katritch et al., 2009; Reynolds et al., 2009). Furthermore, it has been possible to compare the structures of inactive rhodopsin and its active opsin coun-

terpart (Scheerer et al., 2008). Binding of an agonist occurs as a multistage process in which successive conformational changes increase the stability of the drug-receptor interaction (Liapakis et al., 2004; Swaminath et al., 2005). The conformational changes at the extracellular ends of helices III, IV, V, and VII are transmitted via changes in the interactions between key amino acid side chains and water molecules in a hydrogen-bonded network that extends toward the cytoplasmic domain of the receptor (Rosenbaum et al., 2007). The active opsin structure indicates that upon receptor activation, the C terminus of  $G\alpha$  subunits binds within a cavity created by outward tilting of helix VI, altered positioning of helix V, and restructuring of the link between helices VII and VIII (Scheerer et al., 2008).

It is reasonable to suppose that each distinct agonist produces at least subtle differences in the conformation of the ligand binding pocket; however, the key question posed by the demonstration of functional selectivity is whether each agonist also produces a unique conformation at the cytoplasmic face of the receptor. Rosenbaum and coworkers (2007) suggest that the core hydrogen-bonded network allows structural flexibility to the receptor, potentially dampening the capacity of different ligands to induce distinct active conformations. This may be the case, for example, between norepinephrine and epinephrine, which show no bias at the  $\alpha_{1A}$ -AR. However our demonstration of functional selectivity between norepinephrine and the other agonists tested is consistent with the idea that the receptor conformational changes induced by distinct compounds can be transmitted to unique active conformations. We suggest that any demonstration of bias for one pair of signaling outputs must indicate the presence of distinct active conformations. For example, there is clear bias between phenylephrine and norepinephrine when we compare ECAR with either  $Ca^{2+}$  release or cAMP accumulation, but not when we compare  $Ca^{2+}$  release and cAMP accumulation with each other. This cannot imply that the active conformations promoted by phenylephrine and norepinephrine are the same but rather that effector proteins for  $Ca^{2+}$  release and cAMP signaling are not sensitive to the conformational difference. In contrast, there is clear bias between two of the imidazolines (cirazoline and A61603) and norepinephrine when we compare  $Ca^{2+}$  release with cAMP accumulation. In this case, the particular receptor conforma-

TABLE 3

Potency ( $pEC_{50}$ ), maximum response ( $E_{max}$ ), and  $\alpha$  value ( $E_{max}$  relative to norepinephrine) of the endogenous agonists norepinephrine and epinephrine at the  $\alpha_{1A}$ -AR

	$Ca^{2+}$ Release	cAMP	ECAR
Norepinephrine			
$pEC_{50}$	$8.83 \pm 0.06$	$5.55 \pm 0.07$	$7.49 \pm 0.09$
$E_{max}$	$84.4 \pm 1.9$	$32.8 \pm 0.9$	$159.3 \pm 2.7$
$\alpha$	1.00 (9)	1.00 (7)	1.00 (8)
Epinephrine			
$pEC_{50}$	$9.32 \pm 0.08$	$5.83 \pm 0.08$	$7.93 \pm 0.06$
$E_{max}$	$86.6 \pm 2.3$	$31.4 \pm 0.8$	$159.9 \pm 1.6$
$\alpha$	1.03 (9)	0.96 (7)	1.00 (8)

TABLE 4

Transduction ratios for norepinephrine and epinephrine at the  $\alpha_{1A}$ -AR

LogTR is the log of the transduction ratio ( $\tau/K_A$ ), and  $\log TR_n$  values are normalized to the logTR for norepinephrine.

Agonist	$Ca^{2+}$ Release ( $n = 9$ )		cAMP ( $n = 7$ )		ECAR ( $n = 8$ )	
	logTR	$\log TR_n$	logTR	$\log TR_n$	logTR	$\log TR_n$
Norepinephrine	$8.78 \pm 0.09$	$0.00 \pm 0.16$	$5.59 \pm 0.08$	$0.00 \pm 0.12$	$7.49 \pm 0.09$	$0.00 \pm 0.13$
Epinephrine	$9.33 \pm 0.08$	$0.55 \pm 0.16$	$5.78 \pm 0.08$	$0.19 \pm 0.12$	$7.94 \pm 0.09$	$0.45 \pm 0.12$

TABLE 5

Calculation of bias factors for norepinephrine and epinephrine at the  $\alpha_{1A}$ -AR

LogTR is the log of the transduction ratio ( $\tau/K_A$ ), and  $\log TR_n$  values are normalized to the logTR for norepinephrine. To avoid propagation of error due to multiple data manipulation steps, Student's  $t$  tests were carried out on the raw logTR data rather than data normalized to norepinephrine (see Supplemental Table 1).  $P < 0.05$  was considered significant.

	$\log TR_n$ [pathway 1-pathway 2]		
	[cAMP- $Ca^{2+}$ ] (Bias factor)	[ECAR-cAMP] (Bias factor)	[ECAR- $Ca^{2+}$ ] (Bias factor)
Norepinephrine	$0.00 \pm 0.20$ (1.0)	$0.00 \pm 0.18$ (1.0)	$0.00 \pm 0.21$ (1.0)
Epinephrine	$-0.36 \pm 0.20$ (0.43)	$0.26 \pm 0.17$ (1.8)	$-0.10 \pm 0.20$ (0.79)



tions induced by cirazoline and A61603 must favor coupling to effectors for the cAMP pathway over  $G\alpha_q$  coupling.

Our findings concerning the activity of norepinephrine, epinephrine, and phenylephrine at the  $\alpha_{1A}$ -AR are of considerable interest from a structural viewpoint. Phenylephrine but not epinephrine showed substantial bias toward ECAR compared with the other two pathways. Whereas the structure of phenylephrine differs from norepinephrine by two elements, the only difference between epinephrine and phenylephrine is the *para*-hydroxyl on the catechol ring. Modeling and structure-function studies of the  $\beta_2$ -AR have shown that each element within the catecholamine structure interacts with particular amino acid side chains in the ligand-binding pocket (Liapakis et al., 2004; Swaminath et al., 2004). The hydroxyl groups on the catechol ring undergo hydrogen bonding with Ser203 (5.42), Ser204 (5.43), and Ser207 (5.46), the chiral  $\beta$ -hydroxyl interacts with Asn293 (6.55), the aromatic ring undergoes hydrophobic interaction with Phe290 (6.52), and the bioamine  $-\text{NH}_3^+$  group interacts with Asp113 (3.32). In addition, the amine substituent group present in full agonists such as epinephrine and isoproterenol may interact with unidentified residues in TM6 and/or TM7 (Liapakis et al., 2004; Swaminath et al., 2004). The  $\alpha_{1A}$ -AR has only two serine residues in TM5, Ser188(5.42) and Ser192(5.46), whereas the  $\alpha_{1B}$ -AR and  $\alpha_{1D}$ -AR, like the  $\beta_2$ -AR, have all three serines. Our data suggest that the absence of the *para*-hydroxyl in phenylephrine is associated with a key conformational difference in TM5 compared with epinephrine, which has an otherwise identical structure. Although this difference does not affect the capacity of phenylephrine to promote  $G\alpha_q$  coupling, it does increase coupling to effectors for ECAR. It would be interesting to test whether a ligand that lacks both the *para*-hydroxyl and the *N*-methyl group (norphenylephrine) also shows bias toward ECAR, and to compare the behavior of all these compounds at the  $\alpha_{1A}$ -AR and  $\alpha_{1B}$ -AR that differ in the number of TM5 serine residues. We also intend to use high-throughput signaling assays to identify the nature of effectors that promote changes in ECAR and are strongly coupled to the  $\alpha_{1A}$ -AR in the presence of phenylephrine.

Another major finding from our study is that norepinephrine and epinephrine display no bias in signaling by the  $\alpha_{1A}$ -AR for the three pathways studied. This raises the question of whether multiple endogenous agonists have in other cases evolved as a result of their capacity for differential signal transduction at particular receptors. Indeed, we have recently demonstrated signaling bias for multiple endogenous agonists of the GLP1 receptor (Koole et al., 2010), and this may be relevant to other GPCRs that possess multiple endogenous ligands, including the chemokine CXCR2 and CCR7 receptors, cholecystokinin CCK1(A), cholecystokinin CCK2(B), endothelin  $\text{ET}_A$  and  $\text{ET}_B$ , melanocortin MC4, purinergic P2Y<sub>2</sub>, GLP2, VPAC1, VPAC2 receptors, and calcitonin and related receptors (list derived from <http://www.iuphar-db.org/DATABASE/GPCRListForward>). The case of adrenoceptors is somewhat different, because both norepinephrine and epinephrine act at nine different receptor subtypes and may display functional selectivity at subtypes other than the  $\alpha_{1A}$ -AR. A major functional difference between the two endogenous agonists is that norepinephrine is a neurotransmitter that is released into synapses and neuromuscular junctions, whereas epinephrine is a circulating hor-

mone that acts on the adrenoceptors present in a wide range of peripheral cell types. Selective pressure to maintain the interaction between adrenoceptor subtypes and two distinct agonists may have arisen primarily because of differences in the cell distribution of the target receptors rather than functional selectivity.

In conclusion, we have shown that a series of agonists at the human  $\alpha_{1A}$ -AR display functional selectivity across three signaling pathways. The analytical method used has allowed us to derive numerical values for the degree of signaling bias and to test for statistical significance. As shown here, a rigorous description of functional selectivity facilitates correlations between ligand structure and the ability to promote distinct active receptor conformations. More generally, this type of analysis will provide a platform for elucidating the mechanistic basis of functional selectivity at GPCRs by suggesting suitable ligands for receptor crystallization, or classes of ligands for modeling studies.

#### Acknowledgments

We thank Maria Papaioannou for excellent technical assistance, Dr. Nathan Hall for helpful discussions, and Dr. Thomas Chang (Roche Bioscience, Palo Alto, CA) for the gift of plasmid containing the human  $\alpha_{1A-4}$ -AR cDNA.

#### Authorship Contributions

*Participated in research design:* Evans, Broxton, Hutchinson, and Summers.

*Conducted experiments:* Broxton, Merlin, Sato, and Hutchinson.

*Contributed new reagents or analytic tools:* Christopoulos.

*Performed data analysis:* Evans and Christopoulos.

*Wrote or contributed to the writing of the manuscript:* Evans, Broxton, Hutchinson, Christopoulos, and Summers.

#### References

- Audet M and Bouvier M (2008) Insights into signaling from the  $\beta_2$ -adrenergic receptor structure. *Nat Chem Biol* **4**:397–403.
- Black JW and Leff P (1983) Operational models of pharmacological agonism. *Proc R Soc Lond B Biol Sci* **220**:141–162.
- Chang DJ, Chang TK, Yamanishi SS, Salazar FH, Kosaka AH, Khare R, Bhakta S, Jasper JR, Shieh IS, Lesnick JD, et al. (1998) Molecular cloning, genomic characterization and expression of novel human  $\alpha_{1A}$ -adrenoceptor isoforms. *FEBS Lett* **422**:279–283.
- Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK, and Lefkowitz RJ (2008)  $\beta$ -arrestin-biased agonism at the  $\beta_2$ -adrenergic receptor. *J Biol Chem* **283**:5669–5676.
- Evans BA, Sato M, Sarwar M, Hutchinson DS, and Summers RJ (2010) Ligand-directed signalling at  $\beta$ -adrenoceptors. *Br J Pharmacol* **159**:1022–1038.
- Figuroa KW, Griffin MT, and Ehlert FJ (2009) Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes. *J Pharmacol Exp Ther* **328**:331–342.
- Galandrin S, Oligny-Longpré G, and Bouvier M (2007) The evasive nature of drug efficacy: implications for drug discovery. *Trends Pharmacol Sci* **28**:423–430.
- Galandrin S, Oligny-Longpré G, Bonin H, Ogawa K, Galés C, and Bouvier M (2008) Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the  $\beta_1$ -adrenergic receptor. *Mol Pharmacol* **74**:162–172.
- Graham RM, Perez DM, Hwa J, and Piascik MT (1996)  $\alpha_1$ -Adrenergic receptor subtypes. Molecular structure, function, and signaling. *Circ Res* **78**:737–749.
- Gregory KJ, Hall NE, Tobin AB, Sexton PM, and Christopoulos A (2010) Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. *J Biol Chem* **285**:7459–7474.
- Horie K, Itoh H, and Tsujimoto G (1995) Hamster  $\alpha_{1B}$ -adrenergic receptor directly activates Gs in the transfected Chinese hamster ovary cells. *Mol Pharmacol* **48**:392–400.
- Hutchinson DS, Bengtsson T, Evans BA, and Summers RJ (2002) Mouse  $\beta_{3a}$ - and  $\beta_{3b}$ -adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signalling pathways. *Br J Pharmacol* **135**:1903–1914.
- Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, Ijzerman AP, and Stevens RC (2008) The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. *Science* **322**:1211–1217.
- Johnson RD and Minneman KP (1986) Characterization of  $\alpha_1$ -adrenoceptors which

- increase cyclic AMP accumulation in rat cerebral cortex. *Eur J Pharmacol* **129**:293–305.
- Katritch V, Reynolds KA, Cherezov V, Hanson MA, Roth CB, Yeager M, and Abagyan R (2009) Analysis of full and partial agonists binding to  $\beta_2$ -adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes. *J Mol Recognit* **22**:307–318.
- Kenakin T (2007) Functional selectivity through protean and biased agonism: who steers the ship? *Mol Pharmacol* **72**:1393–1401.
- Kenakin T and Miller LJ (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. *Pharmacol Rev* **62**:265–304.
- Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, Miller LJ, Summers RJ, Christopoulos A, and Sexton PM (2010) Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner; implications for drug screening. *Mol Pharmacol* **78**:456–465.
- Leff P and Harper D (1989) Do pharmacological methods for the quantification of agonists work when the ternary complex mechanism operates? *J Theor Biol* **140**:381–397.
- Liapakis G, Chan WC, Papadokostaki M, and Javitch JA (2004) Synergistic contributions of the functional groups of epinephrine to its affinity and efficacy at the  $\beta_2$ -adrenergic receptor. *Mol Pharmacol* **65**:1181–1190.
- Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. *J Biol Chem* **193**:265–275.
- Masri B, Salahpour A, Didrikson M, Ghisi V, Beaulieu JM, Gainetdinov RR, and Caron MG (2008) Antagonism of dopamine D2 receptor/  $\beta$ -arrestin 2 interaction is a common property of clinically effective antipsychotics. *Proc Natl Acad Sci USA* **105**:13656–13661.
- McConnell HM, Owicki JC, Parce JW, Miller DL, Baxter GT, Wada HG, and Pitchford S (1992) The cytosensor microphysiometer: biological applications of silicon technology. *Science* **257**:1906–1912.
- Morgan NG, Blackmore PF, and Exton JH (1983) Age-related changes in the control of hepatic cyclic AMP levels by  $\alpha_1$ - and  $\beta_2$ -adrenergic receptors in male rats. *J Biol Chem* **258**:5103–5109.
- Perez DM, DeYoung MB, and Graham RM (1993) Coupling of expressed  $\alpha_{1B}$ - and  $\alpha_{1D}$ -adrenergic receptor to multiple signaling pathways is both G protein and cell type specific. *Mol Pharmacol* **44**:784–795.
- Piascik MT and Perez DM (2001)  $\alpha_1$ -adrenergic receptors: New insights and directions. *J Pharmacol Exp Ther* **298**:403–410.
- Reynolds KA, Katritch V, and Abagyan R (2009) Identifying conformational changes of the  $\beta_2$ -adrenergic receptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators. *J Comput Aided Mol Des* **23**:273–288.
- Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Yao XJ, Weis WI, Stevens RC, et al. (2007) GPCR engineering yields high-resolution structural insights into  $\beta_2$ -adrenergic receptor function. *Science* **318**:1266–1273.
- Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe HW, Hofmann KP, and Ernst OP (2008) Crystal structure of opsin in its G-protein-interacting conformation. *Nature* **455**:497–502.
- Sharpe IA, Thomas L, Loughnan M, Motin L, Palant E, Croker DE, Alewood D, Chen S, Graham RM, Alewood PF, et al. (2003) Allosteric  $\alpha_1$ -adrenoceptor antagonism by the conopeptide rho-TIA. *J Biol Chem* **278**:34451–34457.
- Shibata K, Katsuma S, Koshimizu T, Shinoura H, Hirasawa A, Tanoue A, and Tsujimoto G (2003)  $\alpha_1$ -adrenergic receptor subtypes differentially control the cell cycle of transfected CHO cells through a cAMP-dependent mechanism involving p27<sup>Kip1</sup>. *J Biol Chem* **278**:672–678.
- Strange PG (2008) Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. *Br J Pharmacol* **153**:1353–1363.
- Swaminath G, Deupi X, Lee TW, Lee TW, Thian FS, Kobilka TS, and Kobilka B (2005) Probing the  $\beta_2$  adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. *J Biol Chem* **280**:22165–22171.
- Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, and Kobilka BK (2004) Sequential binding of agonists to the  $\beta_2$  adrenoceptor. Kinetic evidence for intermediate conformational states. *J Biol Chem* **279**:686–691.
- Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. *J Pharmacol Exp Ther* **320**:1–13.
- Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, Leslie AG, Tate CG, and Schertler GF (2008) Structure of a  $\beta_1$ -adrenergic G-protein-coupled receptor. *Nature* **454**:486–491.
- Woo AY, Wang TB, Zeng X, Zhu W, Abernethy DR, Wainer IW, and Xiao RP (2009) Stereochemistry of an agonist determines coupling preference of  $\beta_2$ -adrenoceptor to different G proteins in cardiomyocytes. *Mol Pharmacol* **75**:158–165.
- Yao X, Parnot C, Deupi X, Ratnala VR, Swaminath G, Farrens D, and Kobilka B (2006) Coupling ligand structure to specific conformational switches in the  $\beta_2$ -adrenoceptor. *Nat Chem Biol* **2**:417–422.
- Yao XJ, Vélez Ruiz G, Whorton MR, Rasmussen SG, DeVree BT, Deupi X, Sunahara RK, and Kobilka B (2009) The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. *Proc Natl Acad Sci USA* **106**:9501–9506.
- Zhong H and Minneman KP (1999) Activation of tyrosine kinases by  $\alpha_{1A}$ -adrenergic and growth factor receptors in transfected PC12 cells. *Biochem J* **344**:889–894.

**Address correspondence to:** Prof. R. J. Summers, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, 399 Royal Parade, Parkville, Victoria 3052, Australia. E-mail: roger.summers@monash.edu